Allergan to buy Tobira in push for fatty liver disease drugs
Just hours later on Tuesday, Allergan announced it would also pay $50 million upfront and make future milestone payments for Akarna Therapeutics Ltd, a privately held company that is planning early-stage studies of a treatment for NASH. There are no approved treatments for the disease affecting more than 15 million Americans, which involves accumulation of fat in the liver not caused by alcohol, and can lead to cirrhosis, liver transplants or liver cancer.
Original post:
Allergan to buy Tobira in push for fatty liver disease drugs